📷 Image: Wikimedia Commons / Drmaseeh
Business
US Tariff Plan Sparks Indian Pharma Diversification and Innovation, Experts Say
✍️ Business Standard
🗓 27 Jul 2026, 03:52 AM
👁 3
The US tariff plan has prompted Indian pharmaceutical companies to broaden their product portfolios and invest in new research, experts report.
The United States has introduced a tariff plan that could impact the import of pharmaceutical products, sending shockwaves through India's drug manufacturing sector.
In response, Indian pharma firms are diversifying their product lines and ramping up research and development to lessen reliance on the U.S. market.
Industry analysts note that the tariff move is likely to accelerate domestic R&D investments and encourage the production of generic drugs within India.
The sector is expected to adapt by exploring new export markets and strengthening supply chain resilience.
In response, Indian pharma firms are diversifying their product lines and ramping up research and development to lessen reliance on the U.S. market.
Industry analysts note that the tariff move is likely to accelerate domestic R&D investments and encourage the production of generic drugs within India.
The sector is expected to adapt by exploring new export markets and strengthening supply chain resilience.